ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation (BOREALIS-AF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00580216
Recruitment Status : Terminated (early discontinuation based on strategic sponsor decision not driven by any safety concern)
First Posted : December 24, 2007
Last Update Posted : March 21, 2016
Sponsor:
Information provided by (Responsible Party):
Sanofi

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : October 2010
  Actual Study Completion Date : October 2010
  Certification/Extension First Submitted : February 19, 2016